Neuropsyad | Lisbon is a cutting-edge brand that offers AI-powered neuroimaging biomarkers for Neurology and Psychiatry. They understand the challenges faced by clinicians in diagnosing neurologic and psychiatric disorders, as it heavily relies on subjective impressions, visual inspection of brain scans, and memory. This makes it particularly difficult to diagnose disorders like Alzheimer's and Parkinson's in their early stages, resulting in misdiagnosis for a significant percentage of patients.

Neuropsyad aims to support clinicians by providing them with timely and confident diagnoses. Using artificial intelligence and magnetic resonance imaging, they analyze brain scan data to recognize disease 'signatures' in new patients. Their reports provide a probability score per disease, allowing for personalized and early treatment options.

Not only does this lead to earlier diagnosis and better care, but it also lowers costs significantly. In fact, their diagnoses can be up to 5 times less costly than current methods. Neuropsyad has garnered recognition for their innovation, winning multiple awards and having partnerships with national and international clinical organizations.

They also have an esteemed advisory board consisting of neurology and psychiatry experts from the UK, Germany, USA, and Portugal. Stay updated with their latest news by signing up for their newsletter